Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models.
Adaptive immunity
Dementia with Lewy Bodies
Innate immunity
Parkinson’s disease
T cell
α-Synuclein
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
17 Jul 2020
17 Jul 2020
Historique:
received:
07
04
2020
accepted:
06
07
2020
entrez:
19
7
2020
pubmed:
19
7
2020
medline:
25
5
2021
Statut:
epublish
Résumé
α-Synuclein (α-syn) is a pre-synaptic protein which progressively accumulates in neuronal and non-neuronal cells in neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy. Recent evidence suggests that aberrant immune activation may be involved in neurodegeneration in PD/DLB. While previous studies have often focused on the microglial responses, less is known about the role of the peripheral immune system in these disorders. To understand the involvement of the peripheral immune system in PD/DLB, we evaluated T cell populations in the brains of α-syn transgenic (tg) mice (e.g., Thy1 promoter line 61) and DLB patients. Immunohistochemical analysis showed perivascular and parenchymal infiltration by CD3+/CD4+ helper T cells, but not cytotoxic T cells (CD3+/CD8+) or B cells (CD20+), in the neocortex, hippocampus, and striatum of α-syn tg mice. CD3+ cells were found in close proximity to the processes of activated astroglia, particularly in areas of the brain with significant astrogliosis, microgliosis, and expression of pro-inflammatory cytokines. In addition, a subset of CD3+ cells co-expressed interferon γ. Flow cytometric analysis of immune cells in the brains of α-syn tg mice revealed that CD1d-tet+ T cells were also increased in the brains of α-syn tg mice suggestive of natural killer T cells. In post-mortem DLB brains, we similarly detected increased numbers of infiltrating CD3+/CD4+ T cells in close proximity with blood vessels. These results suggest that infiltrating adaptive immune cells play an important role in neuroinflammation and neurodegeneration in synucleinopathies and that modulating peripheral T cells may be a viable therapeutic strategy for PD/DLB.
Sections du résumé
BACKGROUND
BACKGROUND
α-Synuclein (α-syn) is a pre-synaptic protein which progressively accumulates in neuronal and non-neuronal cells in neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy. Recent evidence suggests that aberrant immune activation may be involved in neurodegeneration in PD/DLB. While previous studies have often focused on the microglial responses, less is known about the role of the peripheral immune system in these disorders.
METHODS
METHODS
To understand the involvement of the peripheral immune system in PD/DLB, we evaluated T cell populations in the brains of α-syn transgenic (tg) mice (e.g., Thy1 promoter line 61) and DLB patients.
RESULTS
RESULTS
Immunohistochemical analysis showed perivascular and parenchymal infiltration by CD3+/CD4+ helper T cells, but not cytotoxic T cells (CD3+/CD8+) or B cells (CD20+), in the neocortex, hippocampus, and striatum of α-syn tg mice. CD3+ cells were found in close proximity to the processes of activated astroglia, particularly in areas of the brain with significant astrogliosis, microgliosis, and expression of pro-inflammatory cytokines. In addition, a subset of CD3+ cells co-expressed interferon γ. Flow cytometric analysis of immune cells in the brains of α-syn tg mice revealed that CD1d-tet+ T cells were also increased in the brains of α-syn tg mice suggestive of natural killer T cells. In post-mortem DLB brains, we similarly detected increased numbers of infiltrating CD3+/CD4+ T cells in close proximity with blood vessels.
CONCLUSION
CONCLUSIONS
These results suggest that infiltrating adaptive immune cells play an important role in neuroinflammation and neurodegeneration in synucleinopathies and that modulating peripheral T cells may be a viable therapeutic strategy for PD/DLB.
Identifiants
pubmed: 32680537
doi: 10.1186/s12974-020-01888-0
pii: 10.1186/s12974-020-01888-0
pmc: PMC7368752
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
214Subventions
Organisme : NIA NIH HHS
ID : R01 AG018440
Pays : United States
Organisme : NIH HHS
ID : AG062429
Pays : United States
Organisme : NIH HHS
ID : AG018440
Pays : United States
Organisme : NIA NIH HHS
ID : Intramural Inter-laboratory Research Program
Pays : United States
Références
J Neurochem. 2016 Oct;139 Suppl 1:240-255
pubmed: 26190401
J Immunol. 2017 Jun 1;198(11):4312-4326
pubmed: 28446566
Scand J Immunol. 2017 May;85(5):321-330
pubmed: 28231624
J Invest Dermatol. 2008 Jun;128(6):1460-9
pubmed: 18079745
Nat Rev Neurol. 2010 Dec;6(12):702-6
pubmed: 21045796
Mol Med Rep. 2015 Oct;12(4):6105-11
pubmed: 26239429
Ann Neurol. 1999 Mar;45(3):353-7
pubmed: 10072050
Nat Rev Neurosci. 2013 Jan;14(1):38-48
pubmed: 23254192
Trends Mol Med. 2011 Dec;17(12):687-8
pubmed: 21996344
Parkinsonism Relat Disord. 2019 Mar;60:25-31
pubmed: 30404763
BMC Neurosci. 2017 Jan 31;18(1):22
pubmed: 28143405
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Nat Commun. 2013;4:1562
pubmed: 23463005
Immunity. 2015 Sep 15;43(3):566-78
pubmed: 26362265
Neurotherapeutics. 2012 Apr;9(2):297-314
pubmed: 22350713
Acta Neuropathol. 2017 Dec;134(6):819-838
pubmed: 28803412
J Neurosci. 2012 Sep 26;32(39):13454-69
pubmed: 23015436
Arch Neurol. 2004 Dec;61(12):1915-9
pubmed: 15596612
J Neuroinflammation. 2015 Dec 18;12:236
pubmed: 26683203
J Neuroimmunol. 2014 Apr 15;269(1-2):1-8
pubmed: 24161471
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5
pubmed: 19651612
Exp Neurol. 2012 Oct;237(2):318-34
pubmed: 22750327
Neurol Sci. 2017 Aug;38(8):1373-1380
pubmed: 28497309
J Neurosci. 2018 Jan 24;38(4):1000-1014
pubmed: 29246926
Mov Disord. 2013 Jan;28(1):31-40
pubmed: 23390095
J Neurosci. 2013 Jun 5;33(23):9592-600
pubmed: 23739956
Parkinsonism Relat Disord. 2005 Dec;11(8):493-8
pubmed: 16154792
Exp Neurobiol. 2016 Jun;25(3):113-9
pubmed: 27358579
J Neuroimmune Pharmacol. 2015 Dec;10(4):645-50
pubmed: 26520433
JAMA Neurol. 2018 Apr 1;75(4):503-509
pubmed: 29459985
J Exp Med. 2012 May 7;209(5):975-86
pubmed: 22508839
J Neuroimmunol. 2012 Nov 15;252(1-2):95-9
pubmed: 22910543
Cell Tissue Res. 2018 Jul;373(1):137-148
pubmed: 29119326
Annu Rev Immunol. 2007;25:297-336
pubmed: 17150027
J Parkinsons Dis. 2013;3(4):493-514
pubmed: 24275605
Cold Spring Harb Perspect Biol. 2011 Dec 01;3(12):
pubmed: 22026965
Brain Pathol. 2016 May;26(3):398-403
pubmed: 26940375
J Neuroimmunol. 2011 Apr;233(1-2):221-7
pubmed: 21239064
Immunobiology. 2016 Feb;221(2):333-40
pubmed: 26517968
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293
pubmed: 28900002
Neurobiol Dis. 2018 Jan;109(Pt B):249-257
pubmed: 28400134
Nat Immunol. 2003 Dec;4(12):1164-5
pubmed: 14639465
J Neurosci. 2016 Jul 27;36(30):7971-84
pubmed: 27466341
Parkinsonism Relat Disord. 2008;14(1):46-51
pubmed: 17702627
Neuron. 1995 Feb;14(2):467-75
pubmed: 7857654
Curr Opin Pharmacol. 2016 Feb;26:87-95
pubmed: 26571205
Cell Tissue Res. 2018 Jul;373(1):161-173
pubmed: 29480459
Front Cell Neurosci. 2015 Aug 05;9:295
pubmed: 26300731
Front Neurosci. 2016 Sep 05;10:408
pubmed: 27656123
J Leukoc Biol. 2007 Nov;82(5):1083-94
pubmed: 17675560
J Neuroimmunol. 2001 Feb 1;113(1):146-52
pubmed: 11137586
J Leukoc Biol. 2017 Oct;102(4):1093-1102
pubmed: 28751472
J Parkinsons Dis. 2015;5(1):1-19
pubmed: 25588354
J Neuroinflammation. 2016 Aug 26;13(1):201
pubmed: 27565429
J Clin Invest. 2009 Jan;119(1):182-92
pubmed: 19104149
J Neuroinflammation. 2016 Jun 30;13(1):174
pubmed: 27364890
Arch Neurol. 2001 Feb;58(2):186-90
pubmed: 11176955
Biochem Pharmacol. 2014 Apr 15;88(4):508-16
pubmed: 24462903
J Neurosci. 2010 Jun 16;30(24):8083-95
pubmed: 20554859
Front Neurosci. 2019 Jan 28;13:28
pubmed: 30745863
Neurobiol Dis. 2018 Jan;109(Pt B):209-218
pubmed: 28751258
Nat Rev Neurol. 2014 Feb;10(2):92-8
pubmed: 24468877
Nat Med. 2017 Feb 7;23(2):1-13
pubmed: 28170377
Lab Invest. 2019 Jul;99(7):971-981
pubmed: 30760864
Front Immunol. 2019 Jan 29;10:80
pubmed: 30761145
J Neuroimmune Pharmacol. 2012 Dec;7(4):927-38
pubmed: 23054369
Ann N Y Acad Sci. 2000;920:16-27
pubmed: 11193145
Nature. 2017 Jun 29;546(7660):656-661
pubmed: 28636593
Acta Neuropathol. 2010 Jun;119(6):657-67
pubmed: 20309568
EMBO J. 2012 May 16;31(10):2378-90
pubmed: 22505026
Annu Rev Med. 2018 Jan 29;69:437-449
pubmed: 29106805
J Neurosci Res. 2002 Jun 1;68(5):568-78
pubmed: 12111846
J Neuroinflammation. 2019 Dec 3;16(1):250
pubmed: 31796095
J Exp Med. 1995 Oct 1;182(4):993-1004
pubmed: 7561702
Front Neurol. 2019 Jan 24;10:13
pubmed: 30733703
Exp Neurobiol. 2019 Oct 31;28(5):547-553
pubmed: 31698547
Heliyon. 2018 Feb 01;4(1):e00513
pubmed: 29560431
Front Pharmacol. 2018 May 04;9:417
pubmed: 29780321
J Neuroimmunol. 2017 Dec 15;313:109-115
pubmed: 29153601
J Neuroimmunol. 2007 Aug;188(1-2):117-27
pubmed: 17582512
Mol Neurodegener. 2018 Aug 9;13(1):43
pubmed: 30092810
Cell. 2018 Jan 25;172(3):517-533.e20
pubmed: 29249358
J Neuroimmune Pharmacol. 2015 Dec;10(4):561-75
pubmed: 26018603
Handb Clin Neurol. 2017;145:339-353
pubmed: 28987181
Brain Res. 2015 Oct 14;1623:63-73
pubmed: 25813828
J Neuroinflammation. 2020 Apr 16;17(1):119
pubmed: 32299492
Front Cell Neurosci. 2018 Oct 02;12:329
pubmed: 30333729
AIDS. 2015 Apr 24;29(7):755-66
pubmed: 25985398
Front Immunol. 2017 Sep 22;8:1178
pubmed: 29018445
J Immunol. 2001 Dec 1;167(11):6525-32
pubmed: 11714821
JAMA Neurol. 2016 Nov 1;73(11):1316-1324
pubmed: 27668667
Acta Neuropathol. 2020 May;139(5):855-874
pubmed: 31993745
Clin Cancer Res. 2005 Oct 15;11(20):7322-7
pubmed: 16243803